Nutex Health Inc. (NUTX) · Aug 6, 2026 · Company update

EPS crushed estimates, but revenue fell short and gains were adjustment-heavy.

EPS crushed estimates, but revenue fell short and gains were adjustment-heavy.

The headline EPS beat was substantial, but revenue missed. Published Q2 expectations were roughly $215–219 million of revenue and $4.95–5.05 of EPS; Nutex delivered $210.8 million of revenue and $9.38 diluted EPS.

MetricQ2 2026Q2 2025Published expectation
Total revenue$210.8M (Income Statement)$244.0M (Income Statement)~$215–219M
Diluted EPS$9.38 (Income Statement)$(2.95) (Income Statement)~$4.95–5.05
Adjusted EBITDA$90.0M (Adjusted EBITDA reconciliation)$71.6M (Adjusted EBITDA reconciliation)—
Operating cash flow, six months$109.7M (Cash Flow statement)$78.2M (Cash Flow statement)—

The earnings beat is real but unusually dependent on cost reversals and accounting items. Contract-services expense fell to $1.1 million from $61.1 million, including a $52.3 million benefit from a retroactive HaloMD agreement amendment and lower CMS arbitration fees (Income Statement; Financial Highlights). Stock-based compensation also shifted from a $78.7 million expense to a $2.9 million expense in the quarter (Income Statement). Those changes lifted operating income to $121.7 million from $33.7 million, so the reported margin improvement is much larger than the underlying revenue trend alone would suggest.

The more durable improvement is lower future arbitration costs, but it is not yet a clean growth result. Management expects the contractual and regulatory changes to reduce normalized historical contract-services expense by roughly 25–30% prospectively (Financial Highlights). That supports better recurring profitability, but hospital revenue declined 14% year over year in the quarter, while same-hospital revenue fell 12.1% (Financial Highlights). Population-health revenue grew to $8.9 million from $7.7 million, but not enough to offset the hospital decline (Income Statement).

Cash generation and the balance sheet improved, though working-capital exposure remains material. Six-month operating cash flow rose to $109.7 million from $78.2 million, and cash plus restricted cash reached $207.1 million (Cash Flow statement). Nutex also spent $50.7 million on stock repurchases and paid $28.6 million in member distributions (Cash Flow statement). However, accounts receivable increased to $351.7 million from $319.4 million at year-end, and long-term debt edged up to $31.1 million from $29.2 million (Balance Sheet), leaving collections and arbitration recoveries important to the cash-flow picture.

Net read: mixed versus expectations. The large EPS beat and lower prospective arbitration-cost structure are meaningful positives, but the revenue miss, double-digit same-hospital contraction, and heavy contribution from a retroactive $52.3 million cost adjustment make this less clean than the headline earnings number suggests.

Original filing on SEC EDGAR

More Nutex Health Inc. news

EPS crushed estimates, but revenue fell short and gains were adjustment-heavy. | NUTX Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.